Blog – Σελίδα 2 – ΕΔΕ – Ελληνική Διαβητολογική Εταιρεία

4 Μαΐου 2026

ΕΔΕ Αρχική Σελίδα, Διάφορα, Νέα και Ανακοινώσεις

IDF Europe Newsletter – April 2026

<!–

FROM SILOES TO COLLABORATION
Advancing liver health through integrated action

As we mark World Liver Day, the European Liver Patients’ Association (ELPA) calls for urgent, coordinated action to address the growing and often overlooked link between liver disease, diabetes and other non-communicable diseases (NCDs).

Metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes share common risk factors and frequently coexist, significantly increasing the
risk of life-threatening complications. Yet across Europe, healthcare systems continue to treat these conditions separately. Too often, people are left to navigate complex systems on their own, moving from one specialist to another for each condition, without coordinated care. This fragmented approach delays diagnosis, limits access to appropriate care and fails to reflect the lived reality of people managing multiple, interconnected conditions.

This must change. We need a decisive shift towards prevention, early detection and integrated, person-centred care to prevent disease progression, reduce complications and improve quality of life.

At EU level, momentum is building through initiatives such as the European cardiovascular health plan, “The Safe Hearts Plan” and the “Healthier Together” NCD framework. These initiatives rightly prioritise prevention, early detection and integrated risk assessment for cardiovascular diseases (CVD) and diabetes. However, they remain incomplete without the full integration of liver health. MASLD is not only highly prevalent but also a major, independent risk factor for CVD.

ELPA therefore calls on the European Institutions and Member States to explicitly include liver health in EU CVD and NCD strategies, and to implement integrated screening
pathways that combine cardiovascular-renal-hepatic-metabolic risk assessments in primary care and in community settings. Simple, non-invasive tools already exist and can identify at-risk populations earlier and more effectively. Health systems must move beyond siloed, disease-specific models and adopt multidisciplinary approaches that address shared risk factors and comorbidities. Ignoring this opportunity means missing a critical window for prevention.

People with lived experience and patient organisations must be at the heart of this transformation. Their meaningful involvement is fundamental to building health systems that truly respond to people’s needs.

Stronger collaboration across the NCD community is also critical. ELPA is proud to be working alongside IDF Europe to advance a more integrated approach to prevention and care. This collaboration is reflected in joint efforts such as the “Bridge the Gap” initiative, which brings together the liver, diabetes, obesity, CVD and kidney communities to align advocacy and promote more coordinated approaches to these interconnected conditions. Our collaboration also includes participation in cross-community events and joint contributions to EU-level policy and advocacy efforts. This work will continue at the ELPA Liver Disease Prevention Village, taking place in front of the European Parliament in the first week of
June. Together, we will join forces to raise awareness, promote screening and prevention, and call on policymakers to take concrete action.

Now is the time to break down siloes, to act together and to make a coordinated, person-centred approach to liver disease, diabetes and other NCDs a reality across Europe.

Beatrice Credi
ELPA Head of Office

IDF EUROPE, NEWS, ACTIVITIES AND EVENTS

Save the date: IDF Europe Symposium at EASD

The IDF Europe Symposium, held during the EASD 62nd Annual Meeting, will take place on Thursday, 1 October, from 10:30 to 12:00 in Milan, and will be followed by a networking lunch.

More information about the Symposium will be available soon. Stay tuned!

IDF Europe Response to the Revision of the Medical Devices and in Vitro Diagnostic Medical Devices Regulation

As the EU moves to revise its medical devices framework (Devices Regulation (MDR) (EU) 2017/745 and In Vitro Diagnostic Medical Devices Regulation (IVDR) (EU) 2017/746), improving efficiency and supporting innovation remain central goals.

IDF Europe welcomes efforts to reduce bottlenecks and speed up access to new technologies, but simplification should not come at the expense of safety, transparency or trust.

In our response to the MDR & IVDR targeted revision, we highlight a key concern: the proposed revision risks shifting too much emphasis from pre-market scrutiny to post-market oversight, without the safeguards needed to ensure patients remain fully protected.

Read our response<!–

Read our response

“Diabetes for Women”
weekend in Poland

On March 6-8, Diabetes Advocate, Adrianna Maciejczyk, organised the “Cukrzyca dla Dziewczyn” (“Diabetes for Women”) Weekend in Poland, bringing together 40 women living with type 1 diabetes (T1D) for education, peer support and empowerment, covering topics from reproductive and mental health to physical activity. IDF Europe Board Member, Prof. Leszek Czupryniak, also participated, sharing insights on CVD risk in women living with diabetes.

We are proud to have endorsed this initiative, which highlights the importance of
advancing sex- and gender-sensitive approaches to diabetes care, a topic we also addressed during our World Diabetes Day 2025 event on women’s health at the European Parliament.

Read more<!–

MIRCIM 2026
Conference in Poland

IDF Europe is pleased to support the McMaster International Review Conference of Internal Medicine (MIRCIM), taking place on May 7–9 in Kraków, Poland.

The conference will gather health experts to discuss the latest evidence, studies and updates to clinical practice guidelines across internal medicine. The programme includes an Annual Update in Diabetology, covering topics from
T1D management to diabetes care in older age groups, as well as a presentation by IDF Europe Board Member, Prof. Leszek Czupryniak, on treatment options for people living with intermediate hyperglycaemia.

A 25% discount is available for all registration types using the code: IDFEurope25%

Person-centred diabetes care: join the San Marino Diabetes Congress

On May 29-30, the San Marino Association of PwD, “Vivere Meglio” (“Living Better”) will host a diabetes congress with the support of IDF Europe, bringing together diabetes advocates, healthcare professionals (HCPs), national diabetes associations and other experts.

The programme will cover key topics including the delivery of high-quality, integrated and person-centred care, the role of health systems, institutions, HCPs and patient associations, the social impact of diabetes and the importance of sport, access to innovation, equity and personalised approaches to care.

Registration is free and open until May 20.

Welcome to the team!

We are delighted to announce three new members to the IDF Europe team: Chantal Michael, Arthur Oury and Elena Thompson.

Chantal Michael joined our team in February as a Research Intern. With a background in Medical and Psychiatric Social Work and currently pursuing a Master’s degree in Global Health, she contributes to our research and policy work. She is particularly motivated by promoting equitable access to care and addressing health disparities.

Arthur Oury came on board in February as a Programme Assistant. Drawing on his background in Social Sciences and International Relations, he plays a key role in supporting project coordination and gathering insights to inform our policy activities. He has a strong interest in European affairs and a keen commitment to collaborative, impact-driven work.

Elena Thompson joined us in April as Communications and Social Media intern. With experience in digital communication and public relations, she leads on managing our social media channels and amplifying our projects and initiatives within the diabetes community. She is especially passionate about making information accessible and helping reduce health inequalities.

MEMBER NEWS

National educational
meeting in Bulgaria

On March 14, the Bulgarian Diabetes Association organised a national educational meeting in Sofia for representatives of its member associations under the theme “Why is diabetes management important?”.

The meeting focused on practical strategies to reduce the risk of diabetes-related complications and strengthen self-management education. Expert
speakers covered key topics such as diabetes management, eye health and prevention of diabetes foot complications. The event provided an opportunity for local diabetes association leaders to exchange knowledge and bring practical insights back to their communities, reinforcing the importance of prevention and proactive diabetes care.

Read more<!–

Celebrating World Health
Day in Uzbekistan

On April 7, marking World Health Day, the Charity Association of Persons with Disabilities and People with Diabetes in Uzbekistan (UMID) organised a community seminar, bringing together 54 residents from rural areas to raise awareness of diabetes prevention and the importance of healthy lifestyles.

Through presentations, videos, interactive sessions, as well as blood glucose and blood pressure checks, the association highlighted the importance of community-based health initiatives in supporting early detection of diabetes and its
complications. It also reinforced the need to ensure equitable access to prevention, diagnosis, education and care for all, particularly in underserved communities.

Read more<!–

Polish Diabetes Association hosts Leaders’ Forum and T2D advocacy workshop

On April 23-24, the 7^thLeaders’ Forum of the Polish Diabetes Association brought together leaders and representatives of people living with diabetes (PwD), marking its 45th anniversary and 35 years as a member of the International Diabetes Federation.

Alongside the Forum, a T2D advocacy workshop led by Oliwia Kaczmarek and
supported by IDF Europe, equipped participants with skills in storytelling, tackling stigma and engaging with decision-makers. With IDF Europe’s Communication & Engagement Manager, Marian Brennan contributing as facilitator and supported by T2GETHER mentors, Christian Petersen, Janne Mikkonen, Oliwia Kacsmarek and Sehnaz Karadeniz, the programme empowered participants living with T2D to translate lived experience into impactful advocacy at national and European levels.

During the event, we were honoured to receive the PRODIABETES Award in recognition of outstanding commitment and contribution to the diabetes community. We sincerely thank the Association for this
meaningful recognition, which means a great deal to our entire team and reflects our ongoing efforts across Europe. We are equally proud that Prof. Leszek Czupryniak, IDF Europe Board Member, was also recognised with an award for his contribution to raising awareness of diabetes and his active participation in public health debates, helping to drive systemic changes that improve the lives of PwD.

Read more<!–

YOUTH PLATFORM

IDF Europe at Thriveabetes 2026

On April 18, IDF Europe Board Member, Jaivir Pall and Youth Coordinator, Joana Amorim, joined Thriveabetes 2026 in Dublin, a conference organised by, and for, people living with T1D. Thriveabetes aims to inform, motivate and inspire the diabetes community by creating a space where no person living with T1D feels alone. The event featured several sessions led by diabetes experts, a Diabetes Technology Exhibition and a Diabetes Research Poster Display.

With a dedicated booth, we showcased the IDF Europe Youth Programme and connected with young PwD and parents interested in becoming part of the community. It was also a valuable opportunity to strengthen relationships with like-minded organisations and raise the visibility of youth advocacy in diabetes across Europe.

Read more about our Youth Programme<!–

UNDERSTANDING DIABETES

Diabetes as a marker of healthcare system resilience

Diabetes is a chronic condition that cuts across all aspects of healthcare systems – from prevention and screening to early intervention, long-term management and complication prevention – requiring coordinated care, access to medicines and technologies, and multidisciplinary teams across all levels of care. It is closely linked to other chronic condtions such as obesity, cardiovascular, liver, kidney and brain diseases, with complications accounting for up to 75% of its costs. Addressing diabetes and its related conditions earlier and more effectively can significantly reduce this burden while strengthening workforce participation and productivity. This requires moving beyond
fragmented approaches toward integrated, person-centred care.

Despite the alarming rise in NCDs, Europe continues to treat the symptoms of a crisis while ignoring its underlying drivers. By the time an EU citizen is diagnosed with a cardiovascular complication, a decade of opportunity for prevention and intervention has already been lost. The EU Safe Hearts Plan is our chance to stop the domino effect through which obesity and diabetes lead to CVD –turning a fragmented system into pillar of resilience for EU’s economy, health systems and its people. For too long, we have addressed interconnected health challenges through siloed approaches. there is a clear opportunity to align screening,
prevention and management of interconnected conditions – supporting more resilient health systems while reinforcing Europe’s long-term competitiveness.

Read more in our article in The Parliament magazine and in the recent EFPIA guest blog co-authored by our Regional Manager, Elisabeth Dupont and Christina Holton Moloney, Co-Chair, EFPIA Obesity Platform:

The Parliament magazine:
“Tackling diabetes is key to creating a healthier, more competitive Europe“

EFPIA guest blog:
“The €240 billion leak: Why Europe’s health resilience starts with integrated obesity, diabetes and CVD health checks“

WHAT WE ARE READING

WHO Europe | Norway’s new legislation shields children from marketing of unhealthy foods

Norway has introduced new legislation banning the marketing of unhealthy food and drinks to children, aiming to tackle rising rates of NCDs. The measure, aligned with WHO recommendations, restricts both traditional and digital advertising and reflects growing international momentum to create healthier environments for children. Norway’s approach is seen as a strong example for other countries in the WHO European Region to follow. Read more

The Lancet Diabetes & Endocrinology | Sleep your way to better metabolic health

A new editorial in The Lancet Diabetes & Endocrinology highlights the often-overlooked link between sleep and metabolic health. It underscores how poor sleep can increase the risk chronic conditions such as T2D, CVD and obesity, particularly in children, through complex, bidirectional mechanisms. The editorial also points to growing evidence that improving sleep could offer a practical and scalable approach to supporting metabolic health. Read more

WHO Europe | New WHO database helps countries turn health data into better policy

WHO has launched the Health Information Systems Governance (HISGOV) database to help countries across the European Region turn health data into better policy. Co-funded by the EU, it compiles nearly 70 indicators on data governance, digital health systems and interoperability. The platform enables comparison across countries, highlights gaps and supports evidence-based decisions to strengthen health systems and improve outcomes. Read more

OECD | Scaling artificial intelligence in health

A new OECD report highlights the potential of artificial intelligence (AI) to improve healthcare if deployed responsibly. It outlines key barriers such as fragmented data, regulatory uncertainty and workforce gaps. To guide countries, it introduces a policy checklist covering enablers, safeguards, public engagement and trustworthy AI deployment, aiming to support coherent strategies, shared learning and balanced innovation across health systems. Read more

WHO Europe | A snapshot of AI in health care across EU Member States

WHO Europe released its first comprehensive assessment of AI in healthcare across the 27 EU Member States. The report shows widespread adoption, with most countries already using AI in diagnostics and patient support, alongside growing investment in workforce training and governance. It highlights the need for stronger skills, public engagement and shared standards to ensure AI improves patient care safely, equitably and with public trust. Read more

EU RESEARCH PROJECTS

ASSESS DHT survey
on DHT evaluation

IDF Europe is part of ASSESS DHT, a Horizon 2020 project aiming to boost the adoption of trustworthy and effective Digital Health Technologies (DHT) across Europe.

Consortium partners are conducting a European survey to increase understanding of how people with lived experience and HCPs can meaningfully contribute to the evaluation of DHT.

The survey is open until May 22

Take the survey<!–

Take the survey

MOVEUP Europe Cup
in Prishtina

IDF Europe is a project partner of MOVEUP, an Erasmus+ project aiming to make physical activity more accessible to people living with T2D and other chronic health conditions.

On April 25-26, 34 participants from Italy, Romania and Kosovo gathered in Prishtina for the MOVEUP Europe Cup, a celebration of walking football, walking basketball and catchball. The event provided an
opportunity for participants involved in the project in their own countries to come together, connect and share experiences with others from across Europe.

DigiCare4You updates

IDF Europe is proud to be part of the DigiCare4You Horizon 2020 project, which aims to improve early prevention and management of T2D and hypertension (HTN).

DigiCare4You final event

The DigiCare4You final event took place on April 29 in Brussels. This high-level gathering brought together policymakers, public health leaders, PwD and other stakeholders to discuss the future of innovative solutions for the prevention and management of T2D and HTN. Participants gained insights into the project’s key achievements and outcomes and also had the opportunity to contribute to the development of a roadmap supporting implementation at national level.

Join the webinar: “From pilot to policy: scaling
DigiCare4You for better NCD Care”

Join the upcoming DigiCare4You interactive webinar on May 19, at 15:00-16:30, to explore how the project is moving beyond pilot initiatives toward real policy-level impact in the prevention and management of NCDs such as T2D and HTN.

The session will feature key findings and results from the project, alongside practical insights on how to implement and scale digital health interventions for NCD prevention and management in your own country. Through expert presentations and dynamic panel discussions, participants will gain a clearer understanding of both the challenges and
opportunities involved in integrating digital health solutions into national systems.

Bulgarian-language video on hypertension

To broaden access to clear and reliable information to a wider audience, the DigiCare4You educational video on HTN has now been translated into Bulgarian.

The video is also available in Albanian, English, Greek and Spanish.

Watch the videos<!–

Watch the videos

Participant interview
with Zacharias Terzakis

DigiCare4You recently published an interview with Zacharias Terzakis, a participant from Greece living with intermediate hyperglycaemia. In the interview, he talks about his motivation, the positive changes he’s noticed and challenges of the programme.

Read the interview<!–

Read the interview

DiaPs: a new digital peer support tool for sport and diabetes

IDF Europe is part of the Erasmus+ project Sports & Diabetes: Diabetes Digital Peer S(up)port (DiaPs), which has been working on developing an app for peer support where PwD can share their experience of managing their condition during sport activities.

Co-created with people living with T1D, the DiaPS app has recently been launched. It aims to empower, inform and connect users, supporting them to stay active in sport with confidence, stay engaged and foster role models for future generations.

As part of the project, PwD, athletes, coaches and PE teachers, HCPs, parents and anyone passionate about sports and diabetes are invited to become DiaPs Ambassadors – exploring the app early, sharing their experience, and helping shape its future development.

Try the DiaPs app<!–

Try the DiaPs app

Become a DiaPs ambassador<!–

Become a DiaPs ambassador

READINGS ON DIABETES

Readings on Diabetes, presented to IDF Europe by Angelo Argenteri, MD, Maria Stella de Sabata, MA, and Andrea Ascoli Marchetti, MD, is a journey through the major diabetes milestones, one of the oldest and still most widespread diseases, with anecdotes, stories, historical facts and a very rich iconography.

Each month, the IDF Europe Newsletter presents a chapter from Readings on Diabetes, which can be downloaded in full here.

14. Scipione Riva Rocci: the sphygmomanometer

In the quiet Ligurian village of San Michele di Pagana rests Scipione Riva Rocci, a name unfamiliar to many, yet central to one of the most important medical tools still in use today: the sphygmomanometer. Simple in design and unchanged in principle for over a century, this device made it possible to measure blood pressure easily and reliably – an essential step forward in modern medicine and in the care of PwD.

Driven by curiosity and influenced by the emerging link between medicine and mechanics, Riva Rocci developed a practical solution at a time when measuring blood pressure was complex and
unreliable. Notably, he chose never to patent his invention, allowing it to spread freely and benefit patients worldwide.

Are you curious to learn about the long quest to understand diabetes? Explore this fascinating story in Chapter 14 of Readings on Diabetes.

Readings on Diabetes<!–

Readings on Diabetes

UPCOMING EVENTS ACROSS EUROPE

Webinar: “The pulse of tomorrow: shifting the paradigm for NCDs in global health architecture”
Online, May 12, 2026, 14:00-15:00 CET | Read more and register here

Webinar: “From pilot to policy: scaling DigiCare4You for better NCD Care”
Online, May 19, 2026, 15:00-16:30 CET | Read more and register here

European Association for the Study of Diabetes (EASD) 62nd Annual Meeting
Milan, September 28 – October 2, 2026 | For more information, click here

IDF Europe Symposium at EASD 2026
Milan, October 1, 2026, 10:30-12:00 CET | More information will be available soon

Follow us on social media!

Make sure to follow us to stay up to date with our latest news and events:

28 Απριλίου 2026

ΕΔΕ Αρχική Σελίδα, Εκδηλώσεις ΕΔΕ, Επιστημονικές Εκδηλώσεις, Ηλεκτρονικά Μαθήματα

ΕΔΕ Webinar (Τετάρτη 6/5/2026, 20:00): “Συνεχής καταγραφή σακχάρου αίματος”

Αγαπητοί συνάδελφοι,

Την Τετάρτη 6/5/2026 στις 20:00 πραγματοποιείται το webinar της Ελληνικής Διαβητολογικής Εταιρείας στο πλαίσιο των μετεκπαιδευτικών της μαθημάτων μέσω διαδικτύου.

ΘΕΜΑ:
“Συνεχής καταγραφή σακχάρου αίματος”

ΠΡΟΕΔΡΕΙΟ / ΣΥΝΤΟΝΙΣΜΟΣ:

Σ. Λιάτης, Παθολόγος – Διαβητολόγος, Διδάκτωρ Ιατρικής Σχολής Πανεπιστημίου Αθηνών, τ. Διευθυντής ΕΣΥ, Επιστημονικός Σύμβουλος Πρότυπου Διαβητολογικού Κέντρου «ATHENS MEDICA».

ΟΜΙΛΙΕΣ:

Α. Παππάς, Παθολόγος – Διαβητολόγος.
Κ. Μαρκάκης, Παθολόγος με Εξειδίκευση στον Σακχαρώδη Διαβήτη, Επίκουρος Καθηγητής Παθολογίας, Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας Πανεπιστημίου Πατρών, Παθολογική Κλινική, Πανεπιστημιακό Γενικό Νοσοκομείο Πατρών.

Σύνδεσμος βιντεοσκοπημένου webinar:

You must be logged in

Προσβλέποντας πάντα στην πολύτιμη ενεργό συμμετοχή σας.

Ο Πρόεδρος της Ε.Δ.Ε.
Κ. Μακρυλάκης

Ο Γεν. Γραμματέας της Ε.Δ.Ε.
Σ. Λιάτης

27 Απριλίου 2026

ΕΔΕ Αρχική Σελίδα, Πληροφορίες για το κοινό

ΚΑΛΟΚΑΙΡΙΝΗ ΔΙΑΤΡΟΦΗ ΚΑΙ ΔΙΑΒΗΤΗΣ

¹Γραμματικού Μαρία, ¹Ζάχας Δημήτρης, ¹Τσάνα Μαρινέλα, ¹Χαρίση Λυδία
Επιμέλεια κειμένου: ¹Δημοσθενόπουλος Χαρίλαος
¹Διαιτολογικό Τμήμα, ΓΝΑ Λαϊκό

Το καλοκαίρι είναι περίοδος ευχαρίστησης και ξεκούρασης για όλους. Είναι διατροφικός κίνδυνος ή μπορούμε να το απολαύσουμε με ευχαρίστηση και χωρίς «απρόοπτα»;

Φρούτα

Τα φρούτα αποτελούν σημαντικό μέρος της καθημερινής διατροφής, αλλά στον διαβήτη χρειάζεται έλεγχος της ποσότητας και του τρόπου κατανάλωσης, λόγω της περιεκτικότητάς τους σε φυσικά σάκχαρα. Συνιστάται η κατανάλωσή τους με μέτρο και ο συνδυασμός τους με πηγές πρωτεΐνης ή λιπαρών, όπως ξηροί καρποί ή τυρί, ώστε να περιορίζονται οι απότομες αυξήσεις της γλυκόζης στο αίμα. Φρούτα με χαμηλότερο γλυκαιμικό δείκτη, όπως οι φράουλες και τα κεράσια, αποτελούν καλύτερες επιλογές, ενώ τα φρούτα του δάσους φαίνεται να έχουν ευνοϊκή επίδραση στα μεταγευματικά επίπεδα γλυκόζης. Το πεπόνι, λόγω μέτριου γλυκαιμικού δείκτη, καλό είναι να καταναλώνεται σε μικρές ποσότητες, ενώ το καρπούζι, αν και έχει υψηλό γλυκαιμικό δείκτη, εμφανίζει χαμηλότερο γλυκαιμικό φορτίο λόγω της υψηλής περιεκτικότητάς του σε νερό. Τα σύκα και τα σταφύλια είναι πλούσια σε σάκχαρα και απαιτούν ιδιαίτερη προσοχή. Επιπλέον, η κατανάλωση λιγότερο ώριμων φρούτων μπορεί να συμβάλει σε καλύτερο γλυκαιμικό έλεγχο.

Ενυδάτωση

Η επαρκής ενυδάτωση πρέπει να αποτελεί βασική προτεραιότητα για τα άτομα με διαβήτη κατά τους θερινούς μήνες, καθώς η νόσος επηρεάζει την ικανότητα του οργανισμού να ρυθμίζει τη θερμοκρασία. Η μειωμένη εφίδρωση και η πιθανή κακή γλυκαιμική ρύθμιση αυξάνουν τον κίνδυνο αφυδάτωσης και θερμικής καταπόνησης. Για τον λόγο αυτό, είναι σημαντικό να αποφεύγονται τα ζαχαρούχα αναψυκτικά και οι χυμοί, ακόμη και οι φυσικοί, λόγω της υψηλής περιεκτικότητάς τους σε σάκχαρα. Προτιμώνται το νερό, το νερό με φυσικά αρώματα (όπως αγγούρι, λεμόνι ή μέντα), η σπιτική λεμονάδα χωρίς ζάχαρη και το κρύο τσάι χωρίς προσθήκη ζάχαρης.

Ώρες γευμάτων

Κατά τη διάρκεια του καλοκαιριού παρατηρείται συχνά μετατόπιση των γευμάτων προς τις βραδινές ώρες, λόγω των υψηλών θερμοκρασιών. Ωστόσο, επιστημονικά δεδομένα δείχνουν ότι ο χρονισμός των γευμάτων επηρεάζει σημαντικά τον μεταβολισμό. Η κατανάλωση τροφής νωρίτερα μέσα στην ημέρα σχετίζεται με καλύτερο γλυκαιμικό έλεγχο, χαμηλότερα επίπεδα μεταγευματικής γλυκόζης και ινσουλίνης, καθώς και με ευνοϊκότερη ρύθμιση του σωματικού βάρους και μεγαλύτερη πιθανότητα διατήρησης της απώλειας βάρους μακροπρόθεσμα. Για τον λόγο αυτό καλό είναι να αποφεύγουμε τα μεγάλα γεύματα το βράδυ, όσο και όταν αυτό είναι εφικτό.

Αλκοόλ

Η κατανάλωση αλκοόλ μπορεί να είναι πιο συχνή κατά τους θερινούς μήνες, συνήθεια που μπορεί να επηρεάσει άμεσα τα επίπεδα γλυκόζης στο αίμα. Ποτά όπως η μπύρα, τα κοκτέιλ και τα ποτά που περιέχουν ζαχαρούχα αναψυκτικά ή σιρόπια μπορούν να οδηγήσουν σε σημαντικές διακυμάνσεις της γλυκόζης. Αν και ορισμένες μελέτες αναφέρουν ότι η μέτρια κατανάλωση αλκοόλ, όπως το κρασί, ενδέχεται να έχει ευνοϊκή επίδραση στο μεταβολικό προφίλ, τα διαθέσιμα δεδομένα παραμένουν αντικρουόμενα και επηρεάζονται από πολλούς παράγοντες, όπως ο τρόπος ζωής αλλά και το γενετικό υπόβαθρο του ατόμου. Οι γενικές συστάσεις περιορίζουν την κατανάλωση σε έως ένα ποτό ημερησίως για τις γυναίκες και έως δύο για τους άνδρες. Παρ’ όλα αυτά, η αποφυγή του αλκοόλ αποτελεί την ασφαλέστερη επιλογή, ιδιαίτερα για άτομα με διαταραγμένο γλυκαιμικό έλεγχο.

Παγωτό και καλοκαιρινά γλυκά

Τα καλοκαιρινά γλυκά, και ιδιαίτερα το παγωτό, καταναλώνονται συχνότερα αυτή την περίοδο και απαιτούν μέτρο. Μια μικρή μερίδα, περίπου μισό φλιτζάνι, θεωρείται πιο κατάλληλη επιλογή. Προτιμώνται προϊόντα με απλά συστατικά ή σπιτικό παγωτό, ενώ ο συνδυασμός με ξηρούς καρπούς μπορεί να συμβάλει σε πιο σταδιακή αύξηση της γλυκόζης. Προϊόντα με ενδείξεις όπως «χωρίς προσθήκη ζάχαρης» ή «υψηλής πρωτεΐνης» περιέχουν συχνά υποκατάστατα ζάχαρης. Αν και φαίνεται να είναι ασφαλή βραχυπρόθεσμα όσον αφορά τον γλυκαιμικό έλεγχο, οι μακροπρόθεσμες επιπτώσεις τους δεν έχουν πλήρως διευκρινιστεί, επομένως συνιστάται η κατανάλωσή τους με μέτρο.

ΒΙΒΛΙΟΓΡΑΦΙΑ

Kenny, G.P., Sigal, R.J. and McGinn, R. (2016). Body temperature regulation in diabetes. Temperature, [online] 3(1), pp.119–145.
Chen, Y.-E., Tsai, H.-L., Tu, Y.-K. and Chen, L.-W. (2026). Effects of timing and eating duration of time restricted eating on metabolic outcomes: systematic review and network meta-analysis. BMJ Medicine, [online] 5(1), pp.e001071–e001071.
Li, X.-H., Yu, F., Zhou, Y.-H. and He, J. (2016). Association between alcohol consumption and the risk of incident type 2 diabetes: a systematic review and dose-response meta-analysis. The American Journal of Clinical Nutrition, [online] 103(3), pp.818–829.
Wiebe, N., Padwal, R., Field, C., Marks, S., Jacobs, R. and Tonelli, M. (2011). A systematic review on the effect of sweeteners on glycemic response and clinically relevant outcomes. BMC Medicine, 9(1).

23 Απριλίου 2026

ΕΔΕ Αρχική Σελίδα, Ηλεκτρονικά Μαθήματα, Νέα και Ανακοινώσεις

Εκπαιδευτικό Πρόγραμμα CME της MedEA – Medical Education Academy με θέμα: “MANAGING PRE-DIABETES/INTERMEDIATE HYPERGLYCAEMIA & TYPE 2 DIABETES 2026: GUIDELINES ON MONITORING & MULTISYSTEM HEALTH”

Εκπαιδευτικό Πρόγραμμα CME της MedEA – Medical Education Academy σε συνεργασία με τον Καθηγητή Antonio Ceriello, με τίτλο: MANAGING PRE–DIABETES/INTERMEDIATE HYPERGLYCAEMIA & TYPE 2 DIABETES 2026: GUIDELINES ON MONITORING & MULTISYSTEM HEALTH

Το πρόγραμμα απευθύνεται σε επαγγελματίες υγείας που διαχειρίζονται ασθενείς με ΣΔτ2, συμπεριλαμβανομένων κλινικών ιατρών που δραστηριοποιούνται στην ενδοκρινολογία, και ιδιαίτερα τον σακχαρώδη διαβήτη, τον προδιαβήτη/ ενδιάμεση υπεργλυκαιμία (IH), τη διαχείριση της παχυσαρκίας και τη γενική ιατρική.

Στο πλαίσιο του προγράμματος θα πραγματοποιηθεί webinar στις 28 Μαΐου 2026, με τίτλο Updated guidelines for the management of IH/T2D, στην αγγλική γλώσσα με ταυτόχρονη μετάφραση σε Ισπανικά και Κινέζικα.

Περισσότερες πληροφορίες για το πρόγραμμα του webinar και την εγγραφή σας, ΔΕΙΤΕ ΕΔΩ

Με εκτίμηση

Το Δ.Σ. της ΕΔΕ

17 Απριλίου 2026

ΕΔΕ Βιβλιογραφική Ενημέρωση

Συνδυαστική συσχέτιση των αγωνιστών του υποδοχέα GLP-1 (GLP-1 RAs) και των συνηθειών υγιεινού τρόπου ζωής με τα καρδιαγγειακά αποτελέσματα σε άτομα με σακχαρώδη διαβήτη τύπου 2: προοπτική μελέτη κοόρτης

Nguyen XT, Li Y, Czernichow S, et al.; VA Million Veteran Program. Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2026 Apr;14(4):317-326. doi: 10.1016/S2213-8587(25)00395-X. PMID: 41763234.

Επιμέλεια: Αναστάσιος Τεντολούρης

ΕΙΣΑΓΩΓΗ – ΣΚΟΠΟΣ

Οι αγωνιστές του υποδοχέα GLP-1 (GLP-1 RAs) έχουν αποδειχθεί αποτελεσματικοί στη μείωση του καρδιαγγειακού κινδύνου σε άτομα με σακχαρώδη διαβήτη τύπου 2 (ΣΔΤ2) και εγκατεστημένη καρδιαγγειακή νόσο. Ωστόσο, οι μακροπρόθεσμες συνδυαστικές επιδράσεις της χρήσης GLP-1 RAs και της υιοθέτησης υγιεινών συνηθειών τρόπου ζωής στα καρδιαγγειακά αποτελέσματα δεν έχουν διερευνηθεί επαρκώς. Σκοπός της παρούσας μελέτης ήταν η διερεύνηση της συνδυαστικής συσχέτισης μεταξύ της χρήσης GLP-1 RAs και της τήρησης οκτώ συνηθειών χαμηλού κινδύνου με τα καρδιαγγειακά αποτελέσματα σε άτομα με ΣΔΤ2.

ΜΕΘΟΔΟΛΟΓΙΑ

Διεξήχθη προοπτική μελέτη κοόρτης στο πλαίσιο του Million Veteran Program (MVP) του Υπουργείου Υποθέσεων Βετεράνων των ΗΠΑ (VA), κατά την περίοδο από τον Ιανουάριο του 2011 έως τον Σεπτέμβριο του 2023. Συμμετείχαν άτομα με σακχαρώδη διαβήτη τύπου 2 (ΣΔΤ2) χωρίς ιστορικό εμφράγματος του μυοκαρδίου, εγκεφαλικού επεισοδίου ή προχωρημένης χρόνιας νεφρικής νόσου. Αξιολογήθηκαν οκτώ συνήθειες χαμηλού κινδύνου: υγιεινή διατροφή, σωματική δραστηριότητα, μη καπνιστική συμπεριφορά, ποιοτικός ύπνος, αποφυγή υπερβολικής κατανάλωσης αλκοόλ, διαχείριση του άγχους, κοινωνική σύνδεση και υποστήριξη, και απουσία διαταραχής χρήσης οπιοειδών. Πρωτεύον καταληκτικό σημείο ήταν τα μείζονα ανεπιθύμητα καρδιαγγειακά συμβάντα (major adverse cardiovascular events, MACE), οριζόμενα ως μη θανατηφόρο έμφραγμα του μυοκαρδίου, μη θανατηφόρο εγκεφαλικό επεισόδιο ή καρδιαγγειακός θάνατος. Ο κίνδυνος εμφάνισης MACE εκτιμήθηκε με χρήση πολυμεταβλητών μοντέλων αναλογικών κινδύνων Cox, σε συνάρτηση με τη χρήση GLP-1 RAs και τον αριθμό των τηρούμενων συνηθειών χαμηλού κινδύνου.

ΑΠΟΤΕΛΕΣΜΑΤΑ

Από τα 963.753 εγγεγραμμένα άτομα, συμπεριλήφθηκαν συνολικά 98.261 συμμετέχοντες, αντιστοιχώντας σε 632.543 ανθρωπο-έτη παρακολούθησης, κατά τη διάρκεια των οποίων καταγράφηκαν 10.443 συμβάντα MACE. Τα κύρια ευρήματα ήταν τα εξής:

Ο πολυμεταβλητά προσαρμοσμένος λόγος κινδύνου (HR) για MACE ήταν 0,40 (95% CI: 0,30-0,54) για τα άτομα που τηρούσαν και τις 8 συνήθειες χαμηλού κινδύνου, σε σύγκριση με εκείνα που τηρούσαν 1 ή καμία.
Ο HR για MACE ήταν 0,84 (95% CI: 0,76-0,92) για χρήστες GLP-1 RAs σε σύγκριση με μη χρήστες.
Τα άτομα που χρησιμοποιούσαν GLP-1 RAs και τηρούσαν 6–8 συνήθειες χαμηλού κινδύνου είχαν κατά 43% χαμηλότερο κίνδυνο εμφάνισης MACE σε σύγκριση με όσους τηρούσαν ≤3 συνήθειες και δεν χρησιμοποιούσαν GLP-1 RAs (HR: 0,57; 95% CI: 0,46-0,71).

ΣΥΜΠΕΡΑΣΜΑΤΑ

Η τήρηση συνηθειών χαμηλού κινδύνου σε συνδυασμό με τη χρήση GLP-1 RAs συσχετίστηκε με μεγαλύτερη μείωση του κινδύνου MACE σε σύγκριση με καθεμία από τις παρεμβάσεις μεμονωμένα. Τα ευρήματα αυτά υπογραμμίζουν τη σημασία της ενσωμάτωσης παρεμβάσεων τρόπου ζωής με τη φαρμακοθεραπεία στη διαχείριση του ΣΔΤ2, αναδεικνύοντας τη συνεργιστική τους δράση. Συνολικά, τα αποτελέσματα ενισχύουν την ανάγκη για μια ολιστική προσέγγιση στη διαχείριση του ΣΔΤ2, που συνδυάζει φαρμακοθεραπεία και τροποποίηση του τρόπου ζωής.

ΒΙΒΛΙΟΓΡΑΦΙΑ

Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. doi: 10.1056/NEJMoa1603827.
Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141.
Xie Y, Bowe B, Xian H, Loux T, McGill JB, Al-Aly Z. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol. 2023 Sep;11(9):644-656. doi: 10.1016/S2213-8587(23)00171-7.

17 Απριλίου 2026

ΕΔΕ Βιβλιογραφική Ενημέρωση

Εθνικές τάσεις στις δαπάνες για αντιδιαβητικά φάρμακα σε ενήλικες με σακχαρώδη διαβήτη στις ΗΠΑ, 2000-2022

Wang Y, Bullard KM, Zhang P. National Trends in Expenditures on Glucose-Lowering Medications in U.S. Adults With Diabetes: 2000-2022. Diabetes Care. 2026 Apr 1;49(4):571-577. doi: 10.2337/dc25-2016. PMID: 41701609.

Επιμέλεια: Αναστάσιος Τεντολούρης

ΕΙΣΑΓΩΓΗ – ΣΚΟΠΟΣ

Η εισαγωγή νέων κατηγοριών αντιδιαβητικών φαρμάκων – όπως οι GLP-1RA και οι SGLT-2 αναστολείς – καθώς και οι αλλαγές στις ασφαλιστικές πολιτικές ενδέχεται να έχουν μεταβάλει σημαντικά τις δαπάνες για τα αντιδιαβητικά φάρμακα. Σκοπός αυτής της μελέτης ήταν η ανάλυση των εθνικών τάσεων των κατά κεφαλήν δαπανών για αντιδιαβητικά φάρμακα σε ενήλικες με σακχαρώδη διαβήτη (ΣΔ) στις ΗΠΑ κατά την περίοδο 2000-2022, συνολικά και ανά υποομάδες πληθυσμού.

ΜΕΘΟΔΟΛΟΓΙΑ

Χρησιμοποιήθηκαν δεδομένα από τις Έρευνες Ιατρικών Δαπανών (Medical Expenditure Panel Survey, MEPS). Η ανάλυση αφορούσε τις ετήσιες κατά κεφαλήν δαπάνες για αντιδιαβητικά φάρμακα σε ενήλικες (≥18 ετών) με αυτοαναφερόμενο ΣΔ. Τα φάρμακα κατατάχθηκαν σε τέσσερις κατηγορίες: (1) παλαιότερα από του στόματος φάρμακα (μετφορμίνη, σουλφονυλουρίες, θειαζολιδινεδιόνες, αναστολείς α-γλυκοσιδάσης, μεγλιτινίδες), (2) νεότερα μη ινσουλινικά φάρμακα (αναστολείς DPP-4, GLP-1 RAs, SGLT2i, ανάλογα αμυλίνης, σύνθετα σκευάσματα), (3) ανθρώπινη ινσουλίνη και (4) ανάλογα ινσουλίνης. Για τον εντοπισμό μεταβολών στις τάσεις εφαρμόστηκε ανάλυση παλινδρόμησης Joinpoint. Εκτιμήθηκαν επίσης οι μεταβολές στον αριθμό των χρηστών και στις δαπάνες ανά χρήστη για κάθε κατηγορία φαρμάκων.

ΑΠΟΤΕΛΕΣΜΑΤΑ

Τα κυριότερα ευρήματα της μελέτης ήταν:

Οι συνολικές κατά κεφαλήν δαπάνες για αντιδιαβητικά φάρμακα αυξήθηκαν κατά 335%, από 856 $ το 2000 σε 3.725 $ το 2022.
Κατά την περίοδο 2000-2012, οι δαπάνες αυξάνονταν κατά 29 $ ετησίως. Μετά το 2012 η αύξηση επιταχύνθηκε σε 224 $ ετησίως.
Καταγράφηκε αξιοσημείωτη αύξηση των δαπανών για νεότερα μη ινσουλινικά φάρμακα (GLP-1RA, SGLT2i, αναστολείς DPP-4), ενώ οι δαπάνες για παλαιότερα από του στόματος φάρμακα και ανθρώπινη ινσουλίνη μειώθηκαν.
Οι δαπάνες για ανάλογα ινσουλίνης αυξήθηκαν αρχικά αλλά σταθεροποιήθηκαν μετά το 2016.
Η ανοδική τάση στα νεότερα φάρμακα υψηλού κόστους οφειλόταν κυρίως στην αύξηση του αριθμού χρηστών.

ΣΥΜΠΕΡΑΣΜΑΤΑ

Οι κατά κεφαλήν δαπάνες για νεότερα αντιδιαβητικά φάρμακα έχουν αυξηθεί σημαντικά κατά τις τελευταίες δύο δεκαετίες στις ΗΠΑ, κυρίως λόγω της ευρύτερης χρήσης αποτελεσματικών αλλά υψηλού κόστους θεραπειών. Η ανάδειξη των βασικών παραγόντων που οδηγούν σε αυτή την αύξηση – συμπεριλαμβανομένης της διεύρυνσης των ενδείξεων, της εξέλιξης των κλινικών κατευθυντήριων οδηγιών και των μεταβολών στην ασφαλιστική κάλυψη – είναι κρίσιμη για τη βελτίωση της προσβασιμότητας και της οικονομικής προσιτότητας των θεραπειών για τον ΣΔ. Τα ευρήματα αυτά υπογραμμίζουν την ανάγκη για στοχευμένες πολιτικές φαρμάκου που θα διασφαλίζουν ισότιμη πρόσβαση για ασθενείς από διαφορετικά κοινωνικοοικονομικά υπόβαθρα.

ΒΙΒΛΙΟΓΡΑΦΙΑ

American Diabetes Association Professional Practice Committee for Diabetes*; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care1 January 2026; 49 (Supplement_1): S183–S215. https://doi.org/10.2337/dc26-S009
Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013. JAMA. 2016;315(13):1400-1402. doi: 10.1001/jama.2016.0126.
Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and health condition, 1996-2016. JAMA. 2020;323(9):863-884. doi: 10.1001/jama.2020.0734.

17 Απριλίου 2026

ΕΔΕ Βιβλιογραφική Ενημέρωση

Σύστημα αυτοματοποιημένης χορήγησης ινσουλίνης χωρίς σωληνάκι έναντι πολλαπλών ημερήσιων ενέσεων σε παιδιά και ενήλικες με σακχαρώδη διαβήτη τύπου 1 και αυξημένη HbA1c (RADIANT): Πολυκεντρική τυχαιοποιημένη κλινική μελέτη

Wilmot EG, Beltrand J, Guerci B, et al. Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. 2026 Apr;14(4):305-316. doi: 10.1016/S2213-8587(25)00364-X. PMID: 41747751.

Επιμέλεια: Αναστάσιος Τεντολούρης

ΕΙΣΑΓΩΓΗ – ΣΚΟΠΟΣ

Τα συστήματα αυτοματοποιημένης χορήγησης ινσουλίνης (Automated Insulin Delivery, AID) έχουν αποδειχθεί αποτελεσματικά στη βελτίωση της γλυκαιμικής ρύθμισης σε άτομα με σακχαρώδη διαβήτη τύπου 1 (ΣΔΤ1) που χρησιμοποιούν αντλία ινσουλίνης. Ωστόσο, δεν υπήρχαν έως τώρα τυχαιοποιημένες μελέτες που να αξιολογούν τα οφέλη των συστημάτων AID χωρίς σωληνάκι (tubeless) τόσο σε ενήλικες όσο και σε παιδιά με υποβέλτιστη γλυκαιμική ρύθμιση, σε σύγκριση με πολλαπλές ημερήσιες ενέσεις ινσουλίνης (Multiple Daily Injections, MDI). Στόχος της μελέτης RADIANT ήταν η αξιολόγηση της ασφάλειας και της αποτελεσματικότητας ενός tubeless AID συστήματος σε σχέση με τις MDI σε αυτόν τον πληθυσμό.

ΜΕΘΟΔΟΛΟΓΙΑ

Η RADIANT ήταν μια πολυκεντρική, διεθνής, παράλληλων ομάδων, τυχαιοποιημένη, ελεγχόμενη κλινική δοκιμή ανοιχτής σχεδίασης, που διεξήχθη σε 19 νοσοκομεία του Ηνωμένου Βασιλείου, του Βελγίου και της Γαλλίας. Συμμετείχαν άτομα ηλικίας 4-70 ετών με ΣΔΤ1 που ελάμβαναν MDI και χρησιμοποιούσαν συνεχή παρακολούθηση γλυκόζης (CGM), με HbA1c 7,5-11%. Οι συμμετέχοντες κατανεμήθηκαν τυχαία σε αναλογία 2:1 σε tubeless AID ή συνέχιση MDI (ομάδα ελέγχου). Πρωτεύον καταληκτικό σημείο ήταν η διορθωμένη διαφορά μεταξύ των ομάδων ως προς την HbA1c στις 13 εβδομάδες, η οποία αξιολογήθηκε για ανωτερότητα.

ΑΠΟΤΕΛΕΣΜΑΤΑ

Μεταξύ του Σεπτεμβρίου 2023 και του Απριλίου 2024 τυχαιοποιήθηκαν συνολικά 188 συμμετέχοντες (ομάδα AID: n=125, ομάδα ελέγχου: n=63). Τα κυριότερα αποτελέσματα ήταν:

Στην ομάδα AID, η HbA1c μειώθηκε από 8,1% (SD 0,7; 65 mmol/mol) στην έναρξη σε 7,2% (SD 0,6; 55 mmol/mol) στις 13 εβδομάδες.
Στην ομάδα ελέγχου η HbA1c παρέμεινε σταθερή: από 8,1% (SD 0,6; 65 mmol/mol) σε 8,0% (SD 0,7; 64 mmol/mol).
Η διορθωμένη μέση διαφορά μεταξύ των ομάδων ήταν -0,8% (95% ΔΕ: -1,0 έως -0,6; -8,7 mmol/mol [95% ΔΕ: -10,9 έως -6,6]; p<0,0001).
Δεν καταγράφηκαν επεισόδια σοβαρής υπογλυκαιμίας ή διαβητικής κετοξέωσης σε καμία από τις δύο ομάδες κατά τη διάρκεια της μελέτης.
Αναφέρθηκαν 39 ανεπιθύμητες ενέργειες σε 28 συμμετέχοντες της ομάδας AID και 3 σε 3 συμμετέχοντες της ομάδας ελέγχου. Δύο σοβαρά ανεπιθύμητα συμβάντα (νόσος Kawasaki και οξύ στεφανιαίο σύνδρομο) στην ομάδα AID κρίθηκαν άσχετα με τη συσκευή ή τη διαδικασία της μελέτης.

ΣΥΜΠΕΡΑΣΜΑΤΑ

Τα αποτελέσματα της μελέτης RADIANT καταδεικνύουν την κλινική αποτελεσματικότητα της άμεσης μετάβασης από MDI σε tubeless AID σε ενήλικες και παιδιά με ΣΔΤ1 που δεν επιτυγχάνουν τους γλυκαιμικούς τους στόχους, χωρίς ανησυχίες ασφαλείας. Τα ευρήματα αυτά υποστηρίζουν την ένταξη των tubeless AID συστημάτων ως θεραπευτική επιλογή στο τυπικό θεραπευτικό πλαίσιο για άτομα με ΣΔΤ1 και υπογλυκαιμική ρύθμιση κάτω από τον επιθυμητό στόχο υπό MDI, τόσο στον παιδιατρικό όσο και στον ενήλικο πληθυσμό.

ΒΙΒΛΙΟΓΡΑΦΙΑ

Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet. 2021;397(10270):208-219. doi: 10.1016/S0140-6736(20)32514-9.
Breton MD, Kanapka LG, Beck RW, et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med. 2020;383(9):836-845. doi: 10.1056/NEJMoa2004736.
Kovatchev BP. The artificial pancreas in 2017: the year of transition from research to clinical practice. Nat Rev Endocrinol. 2018;14(2):74-76. doi: 10.1038/nrendo.2017.170.

7 Απριλίου 2026

ΕΔΕ Αρχική Σελίδα, Νέα και Ανακοινώσεις

IDF Europe newsletter – March 2026

<!–
<!–

ADVANCING WOMEN’S RIGHT TO HEALTH

Unmet needs in women’s health still undermine their universal right to health and require urgent and concrete action. This was brought into sharp focus last month during International Women’s Day, under the theme “Rights. Justice. Action.”

Too often, women’s health needs are overlooked. Differences in how health conditions affect women are not consistently reflected in research, diagnosis or care. Medical systems have long been shaped around male-centric data and assumptions, leaving critical gaps in understanding and supporting women’s health. These gaps
have tangible, real-world consequences.

For example, women living with diabetes face challenges linked to both biological and social factors. Hormonal changes across the life course, from puberty and menstruation to pregnancy and menopause, can significantly affect blood glucose patterns, insulin sensitivity and treatment responses, making diabetes management more complex. In addition, gender-related aspects – including caregiving responsibilities, socio-economic inequalities and differences in how symptoms are recognised and acted upon, including a greater likelihood of their being overlooked or misattributed – can have a further impact on access to timely diagnosis and care. Yet clinical protocols, care delivery and
research often fail to adequately reflect these realities, and women remain underrepresented in trials and clinical studies. As a result:

Women are diagnosed, on average, 4.5 years later than men.
Women living with diabetes have a 13 % higher risk of all-cause mortality compared with men.
Women face a 30 % greater risk of cardiovascular mortality than men.
Women living with diabetes are about one-third more likely to develop depression.

Closing the sex- and gender gap requires more than awareness; it demands targeted policy action.

A key opportunity for progress lies in the
European Parliament’s FEMM Committee’s own-initiative report on gender inequalities in health. The report recognises that decades of male-centric medical research have created gaps across the healthcare cycle, from clinical trials and drug development to diagnostics and treatment, and calls for a more inclusive, sex- and gender-sensitive approach to health policy and research. This includes, for example, personalised diagnostic and treatment strategies that take into account hormonal changes and pregnancy-related risks, a dedicated women’s health research agenda, and the importance of designing and testing medical devices for
diverse anatomical characteristics across populations.

Among the voices driving this change is MEP Sirpa Pietikäinen, Member of the MEPs Mobilising for Diabetes Interest Group (MMD) and shadow rapporteur for the SANT opinion on the FEMM report, who emphasises:

“Diabetes does not affect everyone equally. Women face distinct biological challenges linked to hormonal changes throughout their lives, yet these realities are still insufficiently reflected in research, clinical trials and care. Combined with persistent gender biases, this leads to delayed diagnoses and poorer health outcomes. Closing these gaps requires a more inclusive approach, one that places women’s experiences at the heart of decision-making and strengthens sex- and gender-sensitive health policy. The European Parliament’s ongoing work on gender inequalities in health is a key opportunity to drive this change and help build health systems that are more equitable, responsive and fit for all.”

MEP Sirpa Pietikäinen
MMD Member

IDF EUROPE, NEWS, ACTIVITIES AND EVENTS

IDF Europe TEAM Meeting and Regional Council 2026

On March 27–28, we held our TEAM Meeting (Together Everyone Achieves More) bringing together member associations, partners and representatives from other health organisations. Key sessions explored the national implementation of the EU Safe Hearts Plan, the use of AI in association management, the potential and safety of continuous glucose monitors (CGMs) and existing and potential collaborations across chronic disease communities.

The programme featured award lectures from the co-winners of the IDF Europe Advocate Award 2025, Davor Skeledzija and Marcello Grussu, recognising their contributions to diabetes advocacy. The event concluded with a networking dinner, where IDF Europe presented its Exceptional Partnership Award to Maurizio Guidi, from Eli Lilly, and celebrated the 100th anniversary of the Portuguese Diabetes Association (APDP), with a commemorative award received by Prof. Boavida.

On March 29, we met again with our member associations for our annual Regional Council where we reviewed our 2025 activities and outlined our priorities for 2026. The meeting also provided a platform for member associations to present their national initiatives, exchange ideas and explore opportunities for collaboration to strengthen the impact of the IDF Europe network.

IDF Europe Symposium at ATTD 2026

During this year’s ATTD 2026, we hosted a symposium on how innovation and early intervention can improve outcomes for people living with, or at risk of, diabetes. The event focused on three key areas: early-stage type 1 diabetes (T1D) detection and monitoring, including the role of language and communication; protecting heart health through effective diabetes prevention and management; and the use of CGMs in preventing and managing diabetes and obesity.

We extend our sincere thanks to our moderator, Jaivir Pall, and to all those who joined the symposium, and especially to our speakers, Dr Sufyan Hussain, Marissa Town, Prof. Tsvetalina Tankova and Dr. Sanja Klobučar, for their insightful and engaging presentations.

New publication on T1D screening

During our ATTD symposium, IDF Europe Board Member, Dr. Sufyan Hussain, officially launched a new publication: “An international consensus on screening and monitoring early-stage type 1 diabetes: a roadmap to European implementation”.

Supported and facilitated by IDF Europe, the paper summarises the latest evidence on early T1D screening and provides policy recommendations to guide decision-makers across Europe in implementing effective screening programmes.

Read more<!–

IDF Europe Expert Day report:
advancing diabetes prevention and care

Last December, we convened an Expert Day bringing together people living with diabetes (PwD), healthcare professionals (HCPs), researchers and policymakers to explore the latest advances in diabetes prevention and care. Discussions highlighted key innovations, from T2D remission to progress towards a functional cure for T1D, and how these advances can improve health outcomes across Europe.

The event report captures the key evidence and insights from the event, alongside policy actions needed to bridge the gap between scientific progress and
real-world care.

We extend a heartfelt thank you to all contributors and participants, as well as partner organisations including the European Liver Patients’ Association, the European Society of Cardiology and the European Kidney Health Alliance.

Read the report<!–

Read the report

IDF Europe meets
President Metsola

On March 20, we had the pleasure of meeting with European Parliament President, Roberta Metsola, alongside Chris Delicata, IDF Europe Advisor and President of the Maltese Diabetes Association, to discuss ways to strengthen the prevention, management and care of chronic conditions such as diabetes.

We warmly thank President Metsola for her long-standing support for the diabetes community and her strong commitment to advancing EU policies that improve health outcomes and quality of life for PwD and those at risk.

EU Commission Conference
on medical devices

On March 16, IDF Europe Director of Strategy & Policy, Sabine Dupont, participated in the European Commission High-Level Conference on “Medical devices: innovation and patient safety”.

As part of one of the breakout sessions, she presented a case study on CGMs, highlighting the need for harmonised standards to ensure
safe and effective medical devices are placed on the market. The session emphasised the importance of robust and transparent clinical evidence to inform procurement decisions and support high-quality clinical practice.

IDF Europe at the FOKUS Patient Event

On March 16-17, IDF Europe Regional Manager, Elisabeth Dupont, participated in the FOKUS Patient Event in Stockholm, contributing to panel discussions on dementia prevention and the links between chronic conditions such as diabetes and brain health.

The discussion underscored the importance of recognising the interconnectedness of non-communicable diseases (NCDs) and the need for integrated approaches to prevention, early detection and management.

ESWI-IDC meeting on respiratory infections

On March 5, IDF Europe Chair-Elect, Prof. Raposo, joined the kick-off meeting of the Interdisciplinary Disease Collaboration (IDC) on Respiratory Infections and NCDs, organised by the European Scientific Working group on Influenza (ESWI), and contributed to discussions on the link between diabetes and respiratory infections.

The exchange emphasised the importance of strengthening infection prevention within diabetes care, improving vaccination uptake and collaboration across disciplines.

Save the date: IDF Europe Symposium at EASD

The IDF Europe Symposium, held during the EASD 62nd Annual Meeting, will take place on Thursday, 1 October, from 11:00 to 12:30 in Milan, and will be followed by a networking lunch.

More information about the Symposium will be available soon. Stay tuned!

MEMBER NEWS

Join the Blue on Sail initiative by the Hellenic Diabetes Federation

In August 2025, the Hellenic Diabetes Federation (ELODI) launched the Blue on Sail initiative, a public awareness and educational project combining diabetes education with the values of teamwork, endurance and freedom inspired by sailing. Blue on Sail 2 returns on May 9–11 in Lefkada, offering a unique, life-changing sailing experience for PwD. Participation is free! If you are 18+ and living with diabetes, don’t miss this opportunity.

Read more<!–

Registration form<!–

Registration form

Join the DiaVolley Cup
by Diador in Bratislava, Slovakia

The DiaVolley Cup will take place from July 15–18, 2026 in Bratislava, Slovakia. Hosted by IDF Europe member, Diador, this mixed volleyball tournament brings together adults living with diabetes for four days of sport, teamwork and community building.

All participants must be 18 or older and live with diabetes.

Team registration close on April 14.

Read more<!–

Registration form<!–

Registration form

The 24th Panhellenic
Diabetes Conference

On March 18-21, the Hellenic Diabetes Association held the 24th Panhellenic Diabetes Conference, bringing together over 1,800 participants to discuss the latest advances in diabetes care, prevention and management.

A highlight of the event was the Aretaios Lecture delivered by Prof. Tadej Battelino, IDF Europe Regional Chair, on “Time in tight
range: early detection and reversal of hyperglycemia”, in recognition of his contribution to the field.

Read more<!–

Diabetes Conference in North Macedonia

The Union of Associations of Persons with Diabetes of Macedonia marked its 25th anniversary with a community-focused conference on March 20–21. IDF Europe representatives Uroš Bogdanović, Elisabeth Dupont and Maya Victorova contributed to sessions on youth advocacy, European collaboration and person-centred care, and joined side meetings with national health authorities and local diabetes associations to discuss
policy changes to improve access to diabetes care for PwD in North Macedonia.

Read more<!–

“Football is Medicine”:
promoting physical activity
through football

During the IDF Europe Regional Council 2026 in Ljubljana, participants were introduced to “Football is Medicine”, a research-based initiative to promote physical activity through football. Presented by May-Britt Skoradal, the initiative includes a new manual adapting the approach for people living with T2D. A demonstration session showcased how football fitness can be tailored to different needs.

Those interested in learning more or exploring implementation opportunities are encouraged to get in touch.

Read more<!–

Celebrating 100 years
of the Portuguese Diabetes
Association

During the IDF Europe Regional Council 2026 in Ljubljana, we celebrated the 100th anniversary of the Portuguese Diabetes Association (APDP).

APDP President, Prof. Boavida, delivered a speech reflecting on a century of progress in diabetes care, highlighting APDP’s pioneering role in education, social inclusion and improving quality of life for
PwD, as well as its vision for the future. On this occasion, APDP received an IDF Europe award in recognition of its longstanding contribution to the diabetes community.

Read more<!–

The diabetes community loses an esteemed member in Lyudmila Ivanivna Petrenko

It is with great sadness that we share the news of the passing of Lyudmila Ivanivna Petrenko, President of the International Diabetes Association of Ukraine, whose dedication and leadership made a lasting impact on the diabetes community. Her tireless energy and unwavering commitment transformed diabetes care in Ukraine and saved countless lives. Our deepest condolences go to her family, colleagues and loved ones. Her dedication and achievements will continue to inspire the diabetes community for many years to come.

YOUTH PLATFORM

Applications for the IDF Europe YLL 2026 are now closed

The applications for the IDF Europe Youth Leadership Lab (YLL) 2026 are now closed. We wish to thank everyone who applied as well as our Member Associations and all those who shared news about the YLL with their networks. We received many excellent applications and we will inform the selected participants of the results over the next few weeks.

We look forward to meeting our successful applicants soon!

HEALTH RELATED NEWS

EPF | Recommendations for the trilogue negotiations on the Critical Medicines Act

As trilogue negotiations on the Critical Medicines Act (CMA) are ongoing at EU level, the European Patients’ Forum (EPF) has published a set of recommendations, including the meaningful involvement of people with lived experience throughout CMA implementation and effective EU joint procurement systems to improve the availability, affordability and accessibility of medicines across the EU. Read more

Member States’ initiative to reinstate operating grants for health NGOs under EU4Health

Backed by several EU Member States, France launched an initiative to reinstate operating grants for non-governmental organisations under the EU4Health Programme from 2026 onwards. Operating grants and sustainable funding are essential to ensure civil society organisations can continue bringing the voices and lived experiences of people, including those living with diabetes, into EU health policymaking. Read more

Nature Health, op-ed by Hans Kluge | “A healthy population is a strategic advantage”

In a new op-ed published in Nature Health, WHO Europe Regional Director, Dr. Hans Kluge, argues that health is a strategic investment underpinning security, economic growth and demographic resilience. He highlights that chronic conditions such as diabetes, cardiovascular diseases and cancers drive premature death and lost productivity in Europe. With ageing populations and rising pressures, he stresses that investing in prevention, primary care and healthier living is essential to sustain economies and ensure resilient societies. Read more

EMA | Insulin supply update

The European Medicines Agency (EMA) has issued a notice regarding the discontinuation of certain Eli Lilly insulin presentations containing human insulin, insulin lispro and insulin glargine in selected countries. The specific products affected and the timelines for their withdrawal differ across EU/EEA countries. All discontinuations are expected to occur before Q2 2027, after which the affected insulin presentations will no longer be available. Read more

UNDERSTANDING DIABETES

World Kidney Day: “Caring for people, protecting the planet”

On World Kidney Day (March 12), under the theme “Kidney health for all: caring for people, protecting the planet”, we highlighted the links between kidney disease, diabetes and planetary health.

Environmental factors such as pollution, heat and climate-related disruptions can increase the risk of T2D, complicate glucose management, strain kidney function and disrupt access to medicines and dialysis. In addition, the healthcare sector has a significant environmental footprint.

Prevention, early screening and more sustainable healthcare systems are essential to protect both people and the planet.

World Oral Health Day: “A happy mouth is a happy life”

On World Oral Health Day (March 20), we raised awareness of the importance of oral health and its link with diabetes.

PwD are at higher risk of conditions like gingivitis, cavities, periodontitis and taste impairments due to the changes in the body caused by the condition.

A good oral hygiene routine is important to prevent diabetes-related oral health complications. However, there is still much to learn about the connection between diabetes and oral health.
Further research on oral complications, along with the adoption of integrated care strategies, is key to improving prevention and care for PwD.

EU RESEARCH PROJECTS

ASSESS DHT updates

IDF Europe is part of ASSESS DHT, a Horizon 2020 project aiming to boost the adoption of trustworthy and effective Digital Health Technologies (DHT) across Europe. Consortium partners are currently seeking input from various stakeholders. Explore the open call and surveys:

OPEN CALL
Consortium partners are seeking specialist input to test and help refine the project’s assessment framework for DHT in Europe. We encourage experts in DHT development and Health Technology Assessment (HTA) bodies to join our expert group.

Application deadline: April 17, 2026, 17:00 CET

Learn more<!–

Learn more

SURVEY FOR PATIENTS AND CLINICIANS
Consortium partners are conducting a European survey to increase understanding of how people with lived experience and HCPs can meaningfully contribute to the evaluation of DHT.

Application deadline: April 22, 2026

Participate here<!–

Participate here

SURVEY FOR HTA AND DECISION MAKERS
Consortium partners are also conducting a parallel survey targeting professionals involved in HTA agencies, payer and insurance organisations, ministries and regulatory bodies, hospital-based HTA units and policy and decision-making committees to explore current practices, barriers and opportunities for improving patient and clinical involvement in the evaluation of DHT.

Application deadline: April 22, 2026

Participate here<!–

Participate here

DigiCare4You updates

IDF Europe is proud to be part of the DigiCare4You Horizon 2020 project, which aims to improve early prevention and management of T2D and hypertension (HTN).

Join the DigiCare4You closing event!

The DigiCare4You final event will take place on April 29, in Brussels. This high-level gathering will bring together policymakers, public health leaders, PwD and other stakeholders to shape the future of innovative solutions for the prevention and management of T2D and HTN. Participants will gain insights into the project’s key achievements and outcomes and will also be given the opportunity to contribute to the development of a roadmap to support implementation at national level.

There are still a few available spots for participants to join the event. If you’re interested, please send an email to izabell.thunstrom@idf-europe.org for more information.

Interview with Christina Pelekanou

DigiCare4You recently published an interview with Christina Pelekanou, DigiCare4You implementer from Greece. In the interview, she explains how she supports families, particularly parents living with T2D or intermediate hyperglycaemia, by guiding them in making small, sustainable lifestyle changes at home. She shares how these changes can improve blood glucose, body weight, energy, mood and self-confidence, while also positively influencing children’s health.

“By personalising advice and setting realistic goals, we help families overcome daily challenges and create lasting impact,”
she says.

Watch the interview<!–

Watch the
interview

Participant interview with Stella Vlachou

In another interview, Stella Vlachou, a DigiCare4You participant from Greece living with intermediate hyperglycaemia, shares her experiences. She talks about her motivation to join the programme, the surprises and challenges she faced and the positive changes she has experienced. Stella also reflects on her hopes for the future and how the programme has helped her take concrete steps towards better health.

Read the interview<!–

Read the interview

READINGS ON DIABETES

Each month, the IDF Europe Newsletter presents a chapter from Readings on Diabetes, which can be downloaded in full here.

13. The Leopard

Set during the time of Italy’s unification, “The Leopard” by Giuseppe Tomasi di Lampedusa tells the story of a Sicilian noble family facing a period of major change. As old traditions begin to fade and a new social order emerges, the novel captures this shift through the famous line: “If we want everything to stay as it is, everything must change.”

Alongside its historical story, the novel also includes a powerful and often overlooked element: the impact of diabetes. Through two characters, Tomasi di Lampedusa describes the serious complications of the
disease, including diabetes foot, at a time when little was known about how to treat it.

By bringing together literature, history and medicine, this chapter shows how stories from the past can help us better understand the human side of living with diabetes.

Are you curious to learn about the long quest to understand diabetes? Explore this fascinating story in Chapter 13 of Readings on Diabetes.

Readings on Diabetes<!–

Readings on Diabetes

UPCOMING EVENTS ACROSS EUROPE

DigiCare4You final event
Brussels, April 29, 2026 | For more information, contact izabell.thunstrom@idf-europe.org

European Association for the Study of Diabetes (EASD) 62nd Annual Meeting
Milan, September 28 – October 2, 2026 | For more information, click here

IDF Europe Symposium at EASD 2026
Milan, October 1, 2026 | More information will be available soon

Follow us on social media!

Make sure to follow us to stay up to date with our latest news and events:

Do you want to know more about IDF Europe’s news and events? Please confirm that you are still happy to hear from us!

Give your consent here!<!–

Give your consent here!

@media (max-width:619px){.email-flexible-footer .left-aligned-footer .column,.email-flexible-footer .center-aligned-footer,.email-flexible-footer .right-aligned-footer .column{max-width:100% !important;text-align:center !important;width:100% !important}.flexible-footer-logo{margin-left:0px !important;margin-right:0px !important}.email-flexible-footer .left-aligned-footer .flexible-footer__share-button__container,.email-flexible-footer .center-aligned-footer .flexible-footer__share-button__container,.email-flexible-footer .right-aligned-footer .flexible-footer__share-button__container{display:inline-block;margin-left:5px !important;margin-right:5px !important}.email-flexible-footer__additionalinfo–center{text-align:center !important}.email-flexible-footer .left-aligned-footer table,.email-flexible-footer .center-aligned-footer table,.email-flexible-footer .right-aligned-footer
table{display:table !important;width:100% !important}.email-flexible-footer .footer__share-button,.email-flexible-footer .email-footer__additional-info{margin-left:20px;margin-right:20px}}

3 Απριλίου 2026

ΕΔΕ Αρχική Σελίδα, Νέα και Ανακοινώσεις, Πληροφορίες για το κοινό

Κατασκήνωση ΔΙΑΝΑ 2026

Έβδομη κατασκηνωτική εβδομάδα για παιδιά με Σακχαρώδη Διαβήτη, που διοργανώνει το ΔΙΑΝΑ, Διαβητολογικό Ιατρείο Α΄ Παιδιατρική Νέων Α.Π.Θ. του Ιπποκράτειου Νοσοκομείου Θεσσαλονίκης.

Οι πρακτικές πληροφορίες για την 7η κατασκηνωτική εβδομάδα είναι οι ακόλουθες:

Ημερομηνία: 31/7/2026 – 7/8/2026
Χώρος: κατασκήνωση: «Ελαιώνες», Γομάτι (Πυργαδίκια) Χαλκιδικής
Ηλικίες κατασκηνωτών: 6 ετών – 17 ετών.
Εκδήλωση ενδιαφέροντος και από μεγαλύτερα παιδιά με Σακχαρώδη Διαβήτη σαν ομαδάρχες.

Περισσότερες πληροφορίες στον ακόλουθο σύνδεσμο:

http://dianadiabetes.gr/node/113

3 Απριλίου 2026